# US 2025/0375449 A1 · Pharmaceutical compositions comprising nilotinib

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375449 A1
- Document ID: US20250375449A1
- Status: Published application
- Kind: A1
- Application number: 19/308,419
- Filed: 2025-08-25
- Published: 2025-12-11
- Earliest claimed: 2023-11-08
- Assignees: Xspray Pharma AB
- Applicants: Xspray Pharma AB
- Inventors: Andreas FISCHER; Thomas ANDERSSON
- Web page: https://patentgrep.com/patent/US20250375449A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 35/02: specific for leukemia
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/4816: {Wall or shell material}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein is a composition comprising: an amorphous solid dispersion (ASD) comprising nilotinib and at least one polymeric stabilizing and matrix-forming component; and at least one solid organic acid in admixture with the ASD, and uses thereof in the treatment of proliferative disorder.

## Claims

### Claim 1

A composition comprising:
a particulate amorphous solid dispersion (ASD) comprising nilotinib free base and copovidone; and
ascorbic acid in admixture with the particulate ASD;
wherein the ascorbic acid is present in an amount of from about 0.5 to about 5 times the amount of nilotinib (weight to weight).

### Claim 2 (depends on 1)

The composition of claim 1, wherein the ascorbic acid is present in an amount of from about 1 to about 3 times the amount of nilotinib (weight to weight).

### Claim 3 (depends on 1)

The composition of claim 1, wherein the ascorbic acid is present in an amount of from about 1 to about 1.5 times the amount of nilotinib (weight to weight).

### Claim 4 (depends on 1)

The composition of claim 1, wherein the ascorbic acid is present in an amount of about 1.3 to about 1.6 times the amount of nilotinib (weight to weight).

### Claim 5 (depends on 1)

The composition of claim 1, wherein the particulate ASD consists of nilotinib free base and copovidone.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the nilotinib is present in an amount of about 25% w/w of the particulate ASD.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition has about 0.1 to about 100 ppm of Nilotinib Impurity A.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the ascorbic acid is present in an amount of about 1 to about 1.5 times the amount of nilotinib (weight to weight) and an amount of Nilotinib Impurity A is less than about 6 ppm.

### Claim 9 (depends on 1)

The composition of claim 1 having about 1.4 ppm nilotinib impurity A after 5 weeks when stored at 40° C. and 75% relative humidity.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the particulate ASD has one or more of (1) a bulk density of about 0.42 g/mL, (2) a tapped density of about 0.63 g/mL, and (3) a particle size distribution of about 72% w/w (<125 μm), about 20.8% w/w (125-250 μm), about 5.7% w/w (250-425 μm), about 0.7% w/w (425-600 μm), and about 0.8% w/w (>600 μm).

### Claim 11 (depends on 7)

A pharmaceutical composition comprising the composition of claim 7 and one or more pharmaceutically acceptable excipients.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the ascorbic acid is present in an amount of about 1.3-1.6 times the amount of nilotinib (weight to weight).

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the ascorbic acid is present in an amount of about 1.5 times the amount of nilotinib (weight to weight).

### Claim 14 (depends on 11)

The pharmaceutical composition of claim 11, wherein the particulate ASD has one or more of (1) a bulk density of about 0.42 g/mL, (2) a tapped density of about 0.63 g/mL, and (3) a particle size distribution of about 72% w/w (<125 μm), about 20.8% w/w (125-250 μm), about 5.7% w/w (250-425 μm), about 0.7% w/w (425-600 μm), and about 0.8% w/w (>600 μm).

### Claim 15 (depends on 11)

The pharmaceutical composition of claim 11, wherein the one or more pharmaceutically acceptable excipients comprises a poly(methacrylic acid, ethyl acrylate).

### Claim 16 (depends on 11)

A method for the treatment of a condition in a patient, which comprises: administering to the patient in need thereof the pharmaceutical composition of claim 11 comprising a therapeutically effective amount of nilotinib;
wherein the condition is selected from the group consisting of:
(1) for an adult patient with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and
(2) for adult patients with chronic phase (CP) and accelerated phase (AP) Ph+CML resistant to or intolerant to prior therapy that included imatinib.

### Claim 17 (depends on 1)

An immediate release pharmaceutical composition comprising the composition of claim 1 and one or more pharmaceutically acceptable excipients comprising a poly(methacrylic acid, ethyl acrylate).

### Claim 18 (depends on 6)

An immediate release pharmaceutical composition comprising the composition of claim 6 and one or more pharmaceutically acceptable excipients; wherein an amount of Nilotinib Impurity A is less than about 6 ppm.

### Claim 19 (depends on 17)

A method for the treatment of a condition in a patient, which comprises: administering to the patient in need thereof the pharmaceutical composition of claim 17 comprising a therapeutically effective amount of nilotinib;
wherein the condition is selected from the group consisting of:
(1) for an adult patient with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase; and
(2) for adult patients with chronic phase (CP) and accelerated phase (AP) Ph+CML resistant to or intolerant to prior therapy that included imatinib.

### Claim 20 (depends on 18)

A method for the treatment of a condition in a patient, which comprises: administering to the patient in need thereof the pharmaceutical composition of claim 18 comprising a therapeutically effective amount of nilotinib;
wherein the condition is selected from the group consisting of:
(1) for an adult patient with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase; and
(2) for adult patients with chronic phase (CP) and accelerated phase (AP) Ph+CML resistant to or intolerant to prior therapy that included imatinib.
